Spontaneous bacterial peritonitis (SBP) is a common complication of cirrhotic patients with ascites that usually results in renal failure and death despite the efficacy of the current antibiotic therapy. The pathogenesis of these phenomena is poorly known but it has been related to the production of vasoactive cell mediators locally acting on the splanchnic vasculature. Because previous studies showed that peritoneal macrophages of cirrhotic patients may produce high quantities of vascular endothelial growth factor (VEGF), a powerful vessel permeabilizing agent, when stimulated by cytokines and bacterial lipopolysaccharide, the present study was aimed to seek whether peritoneal macrophages of SBP patients are induced to produce increased amounts of VEGF. Our results indicate that the production rate and the messenger RNA (mRNA) and protein expression of this substance are increased in macrophages of patients with SBP in comparison with those of noninfected cirrhotic patients. This characteristic feature is absent in circulating monocytes of these patients. Moreover, enhanced endothelial cell proliferation induced by conditioned medium of macrophages isolated from the ascites of patients with SBP is abolished by anti-VEGF antibody, and peritoneal tissue of cirrhotic patients expresses both VEGF receptors, Flt-1 and KDR. These results, therefore, are consistent with the concept that locally released macrophagederived VEGF may result in increased vascular permeability and plasma leakage in the peritoneal vessels of cirrhotic patients with SBP. (HEPATOLOGY 2001;34:487-493.) 
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Spontaneous bacterial peritonitis (SBP) is a common complication developed by patients with advanced liver disease and is defined as the infection of a previously sterile ascitic fluid, with no apparent intra-abdominal source of infection. 1, 2 Despite the efficacy of the current antibiotic therapy in resolving peritoneal infection, the mortality rate in cirrhotic patients with SBP still remains relatively high. The pathogenesis of this phenomenon is unclear, although it seems to be related to the development of renal failure, which occurs in approximately 30% of these patients. 3 Cirrhotic patients having a higher inflammatory response at diagnosis of the infection, as estimated by the concentration of tumor necrosis factor ␣ and interleukin 6 in ascites, show a higher incidence of renal failure than those with lower levels of these cytokines. 4 The exact mechanisms linking the inflammatory response to the infection and the development of functional renal failure are not known, but it has been suggested that vascular mediators delivered during the infection could accentuate the arterial vasodilatation already present in cirrhosis, which in turn could trigger the compensatory vasoactive systems leading to renal vasoconstriction and renal failure.
Vascular endothelial growth factor (VEGF) is a powerful mediator of vascular permeability, which was originally named vascular permeability factor because of its ability to induce vascular leakage. 5 Several studies have shown that the plasma extravasation commonly occurring in tumor microvasculature is caused by VEGF and that the effect of this substance on microvessels is more potent than any other mediator of vessel permeability. 6 Recent investigations have shown that peritoneal macrophages of cirrhotic patients can be up-regulated to produce large amounts of VEGF when cultured in the presence of cytokines and bacterial lipopolysaccharide (LPS). 7 Therefore it is reasonable to predict that peritoneal macrophages in cirrhosis may locally direct microvascular permeability by enhancing the synthesis of VEGF under in vivo conditions characterized by the presence of bacterial wall products and/or enhanced concentrations of proinflammatory cytokines, as occurs in SBP.
In the present study we assessed whether peritoneal macrophages of cirrhotic patients with SBP produce increased amounts of VEGF. Our results indicate that the production rate and the messenger RNA (mRNA) and protein expression of this substance are increased in peritoneal macrophages of patients with SBP in comparison with those of noninfected cirrhotic patients. These findings make it attractive to speculate that VEGF could locally increase vessel permeability and plasma leakage in the peritoneal vasculature of patients with cirrhosis, ascites, and SBP.
PATIENTS AND METHODS

Patients.
The investigation was performed in macrophages isolated from ascites of 17 cirrhotic patients (5 women and 12 men) with a mean age of 56 Ϯ 2 years (range, 42 to 73 years). The etiology of cirrhosis was alcohol induced in 3 subjects, hepatitis B surface antigen or hepatitis C antibody associated in 8, both alcohol induced and viral in 3, and cryptogenic in 3. The diagnosis of cirrhosis was established by liver biopsy in 6 cases and by clinical, laboratory, and ultrasonographic findings in the remaining cases. All patients had advanced cirrhosis: 10 belonged to Child-Pugh class B and 7 to Child-Pugh class C. SBP was diagnosed on the basis of a polymorphonuclear (PMN) cell count in ascitic fluid equal to or greater than 250 cells/mm 3 in the absence of clinical, radiologic, or laboratory data suggesting secondary peritonitis or other abdominal disorders resembling SBP (e.g., hemorrhage into ascites, pancreatitis, peritoneal tuberculosis, or carcinoma).
Cell Cultures. Human peritoneal macrophages, either from patients with or without SBP, were prepared and isolated by FicollHypaque gradient centrifugation as previously described. 7, 8 Cells were seeded on 24-well plates (Costar, Cambridge, MA) at a concentration of 6 ϫ 10 5 cells/well and incubated for 12 hours with phenol red-free RPMI 1640 medium supplemented with 2% heat-inactivated fetal calf serum, penicillin/streptomycin (50 U/mL and 50 g/mL) and L-glutamine (2 mmol/L) at 37°C in a humidified atmosphere (95% air and 5% CO 2 ). More than 96% of the adherent cells were nonspecific esterase positive and had the morphologic appearance of macrophages when examined after Giemsa staining.
Peripheral monocytes from healthy subjects (n ϭ 5) and cirrhotic patients with ascites without (n ϭ 5) or with SBP (n ϭ 5) were also isolated. Cells were obtained from fresh blood by venipuncture using acid citrate dextrose as anticoagulant. Blood was centrifuged at 800 rpm (15 minutes, room temperature), and leukocytes were fractionated by Ficoll-Hypaque gradient centrifugation as described above. Peripheral monocytes were seeded on 24-well plates (6 ϫ 10 5 cells/ well) and incubated with supplemented phenol red-free RPMI 1640 medium under standard conditions of humidity and temperature.
Human umbilical vein endothelial cells (HUVEC) were isolated from umbilical cords as described previously. 9 Cells were characterized by morphologic criteria (cobblestone appearance) and by indirect immunofluorescence using an antiserum to human Factor VIII and studied at passage levels 3 and 4.
VEGF Production and VEGF mRNA Expression in Peritoneal Macrophages
of Cirrhotic Patients. Accumulation of VEGF in the culture medium of the isolated human peripheral monocytes or peritoneal macrophages, seeded on 24-well plates, was determined at variable time intervals ranging between 0 and 48 hours. When indicated, medium also contained tumor necrosis factor ␣, 20 ng/mL ϩ interleukin 1␤, 50 U/mL ϩ LPS, 10 g/mL (called MIX hereafter).
Total RNA was extracted from peritoneal macrophages using a commercially available kit (Trizol Reagent; Life Technologies, GIBCO BRL; Gaithersburg, MD). The final RNA pellets were resuspended in diethylpyrocarbonate-treated water and stored at Ϫ80°C until used. Reverse transcription (RT) was performed with random primers using a complementary DNA (cDNA) synthesis kit (Promega, Madison, WI). First strand cDNA synthesis was performed at 42°C for 45 minutes in the DNA thermal cycler (PTC-100, MJ Research Inc., Watertown, MA). Afterwards, the tubes were incubated at 95°C for 5 minutes to stop the reaction. Then each tube was kept at 4°C until polymerase chain reaction (PCR) was performed. PCR was done using a DNA amplification reagent kit (Gibco BRL, Life Technologies) with human VEGF primers prepared by a DNA synthesizer (394 DNA/RNA Synthesizer; Applied Biosystems, Foster City, CA). VEGF primers flanking the insertion/deletion site of human VEGF 165 were designed as described by Mö hle et al. 10 RT-PCR of mRNA encoding the 121-, 165-, and 189-amino acid containing isoforms of VEGF results in PCR products 403, 535, and 607 bp long, 11 respectively. Primers were also synthesized to amplify the cDNA encoding ␤-actin, a constitutively expressed gene, as control. ␤-actin primers were designed and described by Chen et al., 12 giving rise to a 169-bp PCR product in the cDNA base sequence of human ␤-actin. 13 To carry out PCR, 5 L of the RT reaction were added to 45 L of a PCR master mix that contained 5 L of PCR reaction buffer, 0.075 mol MgCl 2 , 50 pmol of VEGF primers, or 25 pmol of ␤-actin primers. The tubes were placed in the DNA thermal cycler and a first incubation at 96°C for 5 minutes was performed. For VEGF this was followed by 25 cycles of the following sequential steps: 30 seconds at 96°C, 60 seconds at 62°C, and 1 minute at 72°C; final incubation at 72°C for 5 minutes. For ␤-actin 22 cycles of the following sequential steps were performed: 30 seconds at 96°C, 30 seconds at 55°C, and 30 seconds at 72°C; final extension was identical to that of VEGF. A negative control of the PCR reaction was included in each set of experiments. The PCR products were size fractionated by agarose gel electrophoresis.
Immunocytochemical Analysis of VEGF Protein Expression. VEGF protein expression was assessed in peritoneal macrophages and cytocentrifuge preparations of ascitic fluid of cirrhotic patients. Macrophages were isolated and seeded on slides placed in P-100 plates as described above. Adherent cells were maintained for 48 hours on culture medium with or without MIX and stored at Ϫ20°C until further processing. Cytocentrifuge preparations were obtained after ascites cell concentration by centrifugation (10 minutes, 1800 rpm, 4°C). Thereafter concentrated ascites samples were placed in a plastic chamber and centrifuged for 5 minutes at 500 rpm (Cytospin 3; Shandon Scientific, Astmoor, England) to seed the cells on the slides, which were immediately treated as described. Preparations were fixed with 100% methanol for 7 minutes at 4°C immediately before the immunostaining. After fixation, they were hydrated with phosphate-buffered saline (PBS) solution for 10 minutes at 4°C and then incubated with 3% H 2 O 2 for 30 minutes at room temperature. After 3 washes with PBS solution, nonspecific staining was blocked with normal rabbit serum (1.5:100 in PBS; Vector Laboratories, Burlingame, CA) for 20 minutes at room temperature. Cell preparations were incubated with goat anti-VEGF polyclonal antibody overnight with a 1:300 dilution in 5% rabbit serum at 4°C. After washing with PBS (3 times for 5 minutes each), cells were incubated with biotinylated rabbit anti-goat Ig G (Vector Laboratories) for 30 minutes. After washing with PBS for 5 minutes at room temperature, preparations were incubated for 30 minutes with horseradish peroxidaseconjugated avidin (Vector Laboratories) and the reaction product was visualized using the 3-3ЈDAB substrate kit for peroxidase (SK-4100, Vector Laboratories). Cells were counterstained with Mayer's hematoxylin. Negative controls were prepared by omitting the primary antibody and their replacement with serum or by preabsorption of the primary antibody with a 5-fold excess of human recombinant VEGF 165 (R&D Systems, Minneapolis, MN).
Endothelial Cell Proliferation Assay. To examine the effect of conditioned medium of peritoneal macrophages cultured for 48 hours on cell proliferation, a microculture (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) (MTT) assay 14 was performed. HUVEC were grown to confluence as described. 7 Cells from confluent culture phase were counted and dispensed within pregelatinized 96-well culture plates in 200 L of medium (approximately 4,800 cells/well). After 24 hours at 37°C, the culture medium was removed, and fresh medium (200 L) containing 100 L of culture supernatant, or vehicle (medium), was added to 12 replicates for each condition studied. Experiments were performed with culture supernatants of peritoneal macrophages isolated from noninfected cirrhotic patients and patients with SBP. Culture plates were incubated for up to 24 hours at 37°C in a 5% CO 2 atmosphere. At the end of this period, 25 L of freshly prepared MTT in Hanks' balanced salt solution (5 mg/mL) was added to the well and MTT incorporated by HUVEC was measured as previously described. 7 In addition, antihuman recombinant VEGF 165 antibody (20 g/mL) was added to the conditioned media and incubated for 2 hours at 37°C. After this preincubation period, the media were used to determine whether the effect on HUVEC proliferation was in fact caused by VEGF. In preliminary experiments we observed that, in the range of 2 to 10 ϫ 10 3 HUVEC/well, a direct linear correlation (r ϭ 0.963) exists between the obtained absorbance and the amount of cells seeded in the well. Viability was assessed routinely using trypan blue exclusion assay.
VEGF Receptors mRNA Expression in Peritoneal Tissue of Cirrhotic
Patients. VEGF receptor transcript expression was assessed in 3 cirrhotic patients undergoing orthotopic liver transplantation. After laparotomy, peritoneal tissue (approximately 200 mg) was collected by serosal scraping from the antimesenteric border of the terminal ileum. Total RNA was extracted from the tissue as described above, and the final RNA was stored at Ϫ80°C until used. RT was performed with DNA-free RNA samples as indicated above. PCR was performed by using a DNA amplification reagent kit. Appropriate sense and antisense primer oligonucleotide was selected from the human cDNA sequences of the Flt-1 receptor 15 and the KDR receptor 16 as described by Couffinhal et al. 17 and Mö hle et al., 10 respectively. The cDNA amplification products were predicted to be 735 bp and 790 bp, respectively.
For the Flt-1 receptor 40 cycles of the following sequential steps were performed: 30 seconds at 95°C, 5 seconds at 56°C, and 1 minute at 72°C and final incubation at 72°C for 10 minutes. For the KDR receptor and after a first incubation at 94°C for 5 minutes, 40 cycles of the following sequential steps were performed: 1 minute at 94°C, 1 minute at 62°C, and 2 minutes at 72°C and final extension was identical to that of Flt-1. Authenticity of VEGF receptor RT-PCR products was confirmed by direct sequencing (373A DNA Sequencer, Applied Biosystems). The sequences were found to be identical to those reported for human Flt-1 and KDR receptors. 15, 16 Control experiments included RNA amplification of each sample without RT and negative control for the PCR step (no cDNA added) to control for contamination of PCR components.
Materials. LPS (E. coli serotype 0127:B8), bovine serum albumin, bovine serum, and MTT were purchased from Sigma Chemical Co. (St. Louis, MO). Hanks' balanced salt solution, and Dulbecco's phosphate-buffered saline were from Bio Whittaker (Walkersville, MD); RPMI 1640, L-glutamine, and streptomycin/penicillin were from GIBCO BRL (Life Technologies, Paisley, Scotland); fetal calf serum was from Reactiva Biological Industries (Kibbutz Beit Haemek, Israel); tumor necrosis factor ␣ was from ImmunoKontact (Frankfurt, Germany); interleukin 1␤ was from Genzyme (Cambridge, MA); NUserum was from Collaborative Res. Inc. (Lexington, MA); endothelial mitogen was from Biomedical Technologies Inc. (Stoughton, MA); human recombinant VEGF 165 and anti-human VEGF 165 antibody for the cell proliferation assays were from R&D; and goat antihuman VEGF 165 antibody for the immunocytochemical studies was from Santa Cruz Biotechnology (SC-152-G; Santa Cruz, CA). Other reagents were obtained from Merck Darmstadt (Darmstadt, Germany). Drugs were prepared fresh daily and concentrations are expressed as the final concentration in the well. VEGF concentration was measured using an enzyme-linked immunosorbent assay (Quantikine Human VEGF Immunoassay; R&D Systems) that recognized the soluble isoforms VEGF 121 and VEGF 165 .
Statistical Analysis. Statistical analysis of the results was performed by using unpaired Student's t test. Data are expressed as mean Ϯ SEM and were considered significant at a P level of .05 or less.
The study was performed according to the criteria of the Investigation and Ethics Committee of the Hospital Clínic Universitari.
RESULTS
Eleven patients included in the study were diagnosed with SBP. The clinical and laboratory data of patients without peritonitis or with SBP are shown in Table 1 . Marked hepatic failure was present in the 2 groups of patients, as indicated by high serum bilirubin and low serum albumin and prothrombin activity.
VEGF Production and VEGF mRNA Expression in Peritoneal
Macrophages. To assess whether cytokines and LPS may affect VEGF production in human macrophages of cirrhotic patients regardless of whether they were isolated from subjects with or without SBP, MIX was added for 48 hours to the cell culture medium of peritoneal macrophages of cirrhotic patients obtained after paracentesis. Confirming previous studies, 7 peritoneal macrophages from noninfected cirrhotic patients with ascites markedly increased VEGF production under MIX stimulatory conditions (from 15.6 Ϯ 2.3 pg/mL to 1,033 Ϯ 146 pg/mL, P Ͻ .001). In addition, the concentration of VEGF in the cell culture medium of macrophages obtained from patients with SBP was significantly higher (705 Ϯ 70 pg/mL, P Ͻ .001) than that found in patients without peritonitis after 48 hours in culture. Interestingly, MIX stimulation also resulted in a further increase in VEGF production in macrophages of patients with SBP (2,824 Ϯ 272 pg/mL, P Ͻ .001), although this effect was of less intensity than that observed in cells obtained from patients without peritonitis.
Time course production of VEGF in peritoneal macrophages isolated from patients without peritonitis or with SBP is shown in Fig. 1 . Macrophages from both groups of patients released significant amounts of VEGF. However, the production rate of this substance was markedly increased in the cells obtained from subjects with SBP as compared with those without peritoneal infection. In fact, as early as 12 hours in culture the concentration of VEGF in the cell culture medium of SBP macrophages was significantly increased in comparison with that in the medium of noninfected macrophages. This difference tended to be more pronounced after 24 hours and 48 hours in culture.
To assess whether increased VEGF protein production in SBP macrophages is associated with enhanced abundance of VEGF mRNA, a semi-quantitative RT-PCR analysis was performed. As shown in Fig. 2 , peritoneal macrophages expressed bands of 403, 535, and 607 bp corresponding to 121, 165, and 189 amino acid isoforms of VEGF, respectively. The expression pattern of these isoforms was found to be similar in macrophages of patients with or without SBP, indicating that the increased VEGF protein production in SBP macrophages is not caused by the existence of unique alternative splicing products of VEGF in these cells. However, analysis of PCR products indicates greater abundance of all 3 transcripts in macrophages of SBP patients. Under the exponential phase of PCR amplification (25 cycles), the 3 bands of VEGF isoforms could be detected in SBP macrophages harvested immediately after paracentesis, the weakest signal corresponding to that of VEGF 189 and the strongest to VEGF 165 . Macrophages of noninfected cirrhotic patients showed the same bands but of less intensity, with the band corresponding to VEGF 189 being barely detectable. This difference in the intensity of the expression of the 3 transcripts between macrophages of patients with or without SBP was also observed when the cells were maintained in culture for 24 hours and 48 hours. Bands of equal strength were obtained using primers for ␤-actin after 22 PCR cycles. Conditioned Medium-Induced Cell Proliferation in HUVEC. The effect of conditioned medium on endothelial cell proliferation, as assessed by MTT incorporation by these cells, is shown in Fig. 3 . After culturing peritoneal macrophages of patients with or without SBP for 48 hours, the conditioned medium was mixed with standard medium at a proportion of 50% and endothelial cell growth in these conditions compared with that observed with standard medium. Cell proliferation induced by conditioned medium obtained from macrophages of patients with SBP was significantly higher than that induced by standard medium or conditioned medium of macrophages without bacterial peritonitis. This difference was abrogated when the conditioned medium of macrophages of patients with SBP also contained the VEGF neutralizing antibody.
Circulating Monocytes Do Not Produce VEGF. To examine whether the increased VEGF production in peritoneal macrophages of cirrhotic patients with SBP is a specific characteristic of these cells or also occurs in other cells of the monocyte/ macrophage cell lineage, the in vitro production of VEGF was also assessed in circulating monocytes isolated from healthy subjects and from cirrhotic patients with ascites, with and without SBP. Neither cells from controls (from 10.2 Ϯ 1.7 to 9.8 Ϯ 1.0 pg/mL) nor those from cirrhotic patients with (from 7.2 Ϯ 2.1 pg/mL to 7.7 Ϯ 1.1 pg/mL) and without SBP (from 5.9 Ϯ 0.7 pg/mL to 5.8 Ϯ 0.6 pg/mL) produced significant amounts of VEGF after 48 hours in culture.
Immunocytochemical VEGF Protein Expression. A representative cell culture of macrophages isolated from ascites of patients with cirrhosis is depicted in Fig. 4A . In agreement with our previous findings showing constitutive VEGF production in peritoneal macrophages of cirrhotic patients with ascites, FIG. 1 . Time-course production of VEGF by peritoneal macrophages of cirrhotic patients with or without SBP. Peritoneal macrophages were isolated from the ascites of 6 cirrhotic patients without SBP and 11 cirrhotic patients with SBP after therapeutical paracentesis. Ascites from each patient was separately processed, the isolated cells were seeded on 24-well plates, and the conditioned medium was assayed for VEGF at the indicated times. Three wells were assayed for each experimental condition. Statistical significances are denoted versus macrophages of cirrhotic patients without SBP under the same experimental conditions. 165 , and VEGF 121 isoforms in peritoneal macrophages of cirrhotic patients with or without SBP are shown. In the RT-PCR, 1 g of total RNA was reverse transcribed by random primers. First-strand cDNA was amplified with human VEGF-specific primers at 25 cycles. Amplification products were for ␤-actin. PCR experiments were made with cells from 3 different patients. FIG. 3 . Proliferation-induced activity of medium from cultured macrophages in HUVEC. Conditioned medium obtained from peritoneal macrophages in culture for 48 hours was added to HUVEC, and changes in growth rate were assessed by MTT incorporation in these cells. ECM, cells cultured with standard endothelial cell medium; CH, cells cultured with ECM and conditioned medium from macrophages of cirrhotic patients; CH ϩ SBP, cells cultured with ECM and conditioned medium from macrophages of cirrhotic patients with SBP; SBP ϩ Ab, cells cultured with ECM containing an antihuman recombinant VEGF 165 antibody and conditioned medium from macrophages of patients with SBP. Statistical significance is denoted vs. ECM cells.
immunoperoxidase staining for VEGF was positive in most of these cells. As expected, the presence of MIX in the cell culture medium of peritoneal macrophages resulted in cell cluster formation, a characteristic phenomenon of activated cells (Fig. 4B) . In addition, MIX induction was also associated with a stronger positive signal for immunoperoxidase VEGF-specific staining.
In an attempt to ascertain whether VEGF protein expression is restricted to peritoneal macrophages or is a generalized characteristic of other cell types found in the ascitic fluid, cytocentrifuge preparations obtained from concentrated ascites were immunostained with the specific VEGF antiserum. As shown in Fig. 4C , mainly macrophages showed a positive reaction for the VEGF antibody, which was not observed in erythrocytes, lymphocytes, or PMN leukocytes. No staining was detected in negative controls (data not shown).
VEGF Receptors in Peritoneal Tissue of Cirrhotic Patients. To explore whether the peritoneum could be a target for the VEGF released by peritoneal macrophages, mRNA expression of the VEGF receptors, Flt-1 and KDR, was assessed in peritoneal tissue of 3 cirrhotic patients. As shown in Fig. 5 , samples from all patients showed a clear band migrating at about 735 bp, which is compatible with the predicted size of the Flt-1 receptor. Similarly, the amplification products corresponding to KDR primers showed a single band of 790 bp in all patients. In both cases, the authenticity of these PCR products was confirmed by direct sequencing.
DISCUSSION
In the current investigation we examined the production of VEGF in ascites fluid macrophages of 11 cirrhotic patients with SBP and 6 patients with cirrhosis and ascites without SBP. Because it is well known that hepatocellular carcinoma is associated with hepatic VEGF gene induction, 18 no patient with this or any other type of cancer was included in the present set of experiments. All but 3 SBP patients showed an enhanced production rate of VEGF as compared with macrophages obtained from cirrhotic patients without SBP. These findings indicate that, despite the clinical heterogeneity that may exist from patient to patient (time of evolution of the disease, days of antibiotic treatment, time of diagnosis of the infection, etc.), induction of VEGF protein overproduction is a rather extended phenomenon in cirrhotic patients with SBP.
The results of our RT-PCR indicated that mRNA encoding the 3 most common isoforms, VEGF 121 , VEGF 165 , and to a lesser extent VEGF 189 , are all expressed by peritoneal fluid macrophages of cirrhotic patients. An identical pattern of alternatively spliced VEGF transcripts was observed in cells isolated from ascites of SBP patients. However, the signal intensity was stronger in the PCR products obtained from macrophages of these patients. This is likely because of both increased transcriptional rate of the gene and greater mRNA stability, because previous experiments showed that LPS and cytokines promote higher VEGF mRNA abundance in cultured peritoneal macrophages of cirrhotic patients through these mechanisms. 7 To determine the biological activity of macrophage-derived VEGF on human endothelial cells, we investigated the effect of macrophage-conditioned media that contained immunoreactive VEGF on the proliferation of HUVEC in vitro. Macrophage-conditioned medium triggered enhanced cell proliferation when derived from SBP patients and this difference was abolished on inhibiting the bioactivity of VEGF by addition of anti-VEGF to the cell culture medium. Together, these findings provide strong evidence that VEGF produced by macrophages from cirrhotic patients with SBP can elicit biological responses from its target cells, the endothelial cells.
Further insight on the cellular origin and cell specificity of the increased VEGF production by ascites fluid macrophages of cirrhotic patients was gained by following 2 distinct exper- imental approaches. First, we determined VEGF production in peripheral monocytes of cirrhotic patients with or without SBP. VEGF release by monocytes of healthy subjects was also assessed. Several studies investigating VEGF release in human monocytic cell lines or peripheral monocytes obtained from healthy subjects found that the production rate of this protein under standard cell culture conditions is almost negligible. 19, 20 This agrees with our results in healthy monocytes. In addition, neither monocytes of cirrhotic patients without peritoneal infection nor those of SBP patients produced significant amounts of VEGF. This sharp contrast between peripheral monocytes and peritoneal macrophages of cirrhotic patients is in agreement with investigations in rodents indicating that macrophages found in the peritoneal lumen are derived from the milky spots of the omentum rather than from circulating peripheral monocytes. 21, 22 Thus, our observations in peritoneal macrophages likely reflect the activity of resident macrophages in the peritoneum. On the other hand, there are several studies indicating that leukocytic cells other than macrophages may also produce VEGF. 23, 24 For this reason, cytocentrifuge preparations of ascites fluid were immunostained for VEGF. As anticipated from the cell culture experiments, we found strong specific immunoreactivity for this protein in macrophages. However, no staining was found in either lymphocytes or PMNs. This finding, therefore, supports the concept that resident peritoneal macrophages are a specific source of VEGF in cirrhotic patients. VEGF was formerly known as vascular permeability factor because it accounts for the hyperpermeability of tumor microvessels to plasma proteins and other circulating macromolecules. [25] [26] [27] In light of these investigations, in the current study we considered the possibility that the accentuation of the arterial vasodilation syndrome in cirrhotic patients with SBP might result from an increased permeability of blood vessels supplying peritoneal lining tissues (mesentery, peritoneal wall and diaphragm) because of increased VEGF secretion by resident phagocytic cells. This, in turn, would accentuate the overactivation of endogenous vasoconstrictor systems, thus precipitating renal failure. Our results showing increased VEGF production and VEGF mRNA expression in peritoneal macrophages of SBP patients and the demonstration of VEGF receptors in the peritoneum are in line with this hypothesis. However, it should be noted that our study cannot establish a direct cause-effect relationship between vessel permeability and macrophage-derived VEGF in cirrhotic patients with SBP.
The biological responses elicited by VEGF-related peptides are mediated by the interaction of these proteins with 2 highaffinity protein tyrosine kinase receptors, Flt-1 (or VEGF-R1) and KDR (VEGF-R2), the human homologue of murine Flk-1. 28 They are predominantly expressed in endothelial cells, although a few additional cell types express one or both of these receptors. [29] [30] [31] [32] [33] In our study, PCR products corresponding to Flt-1 and KDR messengers were obtained in all 3 tissue samples obtained from cirrhotic patients, thus showing the expression of both transcripts in the peritoneal tissue of human cirrhotics.
In summary, the results of the present study show that ascites fluid macrophages of patients with cirrhosis and SBP produce higher quantities of the angiogenic/vasodilator/vasopermeabilizing factor VEGF than ascites fluid macrophages of cirrhotic patients without SBP. Moreover, enhanced endothelial cell proliferation induced by conditioned medium of macrophages isolated from the ascites of patients with SBP is abolished by anti-VEGF antibody. In addition, this characteristic feature is absent in circulating monocytes of these patients and peritoneal tissue of cirrhotic patients expresses both VEGF receptors, Flt-1 and KDR. These results, therefore, are consistent with the concept that locally released macrophagederived VEGF may result in increased vascular permeability and plasma leakage in the peritoneal vessels of cirrhotic patients with SBP. 
